GLP1R and type 2 diabetes mellitus: Semaglutide (Ozempic), a glucagon-like peptide-1 receptor agonist used primarily for the management of type 2 diabetes, has been associated with gastrointestinal side effects, but its potential role in inducing ischemic colitis is not well documented.